- Home
- HASI vs CDTX Comparison
HASI vs CDTX Comparison
Compare HASI & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HASI
- CDTX
- Stock Information
- Founded
- HASI 1981
- CDTX 2012
- Country
- HASI United States
- CDTX United States
- Employees
- HASI N/A
- CDTX N/A
- Industry
- HASI Real Estate Investment Trusts
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HASI Real Estate
- CDTX Health Care
- Exchange
- HASI Nasdaq
- CDTX Nasdaq
- Market Cap
- HASI 3.4B
- CDTX 2.8B
- IPO Year
- HASI 2013
- CDTX 2015
- Fundamental
- Price
- HASI $33.57
- CDTX $219.70
- Analyst Decision
- HASI Strong Buy
- CDTX Buy
- Analyst Count
- HASI 8
- CDTX 13
- Target Price
- HASI $39.50
- CDTX $119.44
- AVG Volume (30 Days)
- HASI 1.4M
- CDTX 2.2M
- Earning Date
- HASI 11-06-2025
- CDTX 11-06-2025
- Dividend Yield
- HASI 5.01%
- CDTX N/A
- EPS Growth
- HASI 27.54
- CDTX N/A
- EPS
- HASI 2.32
- CDTX N/A
- Revenue
- HASI $99,644,000.00
- CDTX N/A
- Revenue This Year
- HASI $184.74
- CDTX N/A
- Revenue Next Year
- HASI N/A
- CDTX N/A
- P/E Ratio
- HASI $14.49
- CDTX N/A
- Revenue Growth
- HASI N/A
- CDTX N/A
- 52 Week Low
- HASI $21.98
- CDTX $15.22
- 52 Week High
- HASI $34.28
- CDTX $220.46
- Technical
- Relative Strength Index (RSI)
- HASI 62.93
- CDTX 88.59
- Support Level
- HASI $31.98
- CDTX $218.86
- Resistance Level
- HASI $33.68
- CDTX $220.46
- Average True Range (ATR)
- HASI 1.19
- CDTX 3.39
- MACD
- HASI 0.04
- CDTX 8.49
- Stochastic Oscillator
- HASI 87.10
- CDTX 99.34
About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.